The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia
Abstract
This intent-to-treat (ITT) analysis was performed to provide a realistic image of the efficacy that could be expected after 26 weeks treatment with a 120-mg dose (40 mg t.i.d.) of EGb 761® (EGb). The data were collected during a 52-week, double-blind, placebo-controlled, fixed dose, parallel-group, multicenter study. Patients were mildly to severely impaired and diagnosed with uncomplicated Alzheimer’s disease or multi-infarct dementia according to ICD-10 and DSM-III-R criteria. The primary outcome measures included the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Geriatric Evaluation by Relative’s Rating Instrument (GERRI) and Clinical Global Impression of Change. From 309 patients included in the ITT analysis, 244 patients (76% for placebo and 73% for EGb) actually reached the 26th week visit. In comparison to the baseline values, the placebo group showed a statistically significant worsening in all domains of assessment, while the group receiving EGb was considered slightly improved on the cognitive assessment and the daily living and social behavior. Mean treatment differences favored EGb with 1.3 and 0.12 points, respectively, on the ADAS-Cog (p = 0.04) and the GERRI (p = 0.007). In the group receiving EGb, 26% of the patients achieved at least a 4-point improvement on the ADAS-Cog, compared to 17% with placebo (p = 0.04). On the GERRI, 30% of the EGb group improved and 17% worsened, while the placebo group showed an opposite trend with 37% of patients worsening for 25% improved (p = 0.006). Regarding safety, no differences between EGb and placebo were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201
Cited by
Alzheimer Disease as a Vascular Disorder: Nosological Evidence
de la Torre, J. C. (2002) · Stroke · doi:10.1161/01.str.0000014421.15948.67 · Cited by 853
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Grimley Evans, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 581
De Smet, P. A. G. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020398 · Cited by 525
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases
Mandel, S., & Youdim, M. B. H. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.04.012 · Cited by 445
Howes, M.-J. R., & Houghton, P. J. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00128-x · Cited by 443
Metadata
- Authors
- Le Bars, P. L., Kieser, M., & Itil, K. Z.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2000
- Volume
- 11
- Issue
- 4
- Pages
- 230-237
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2030329403
- Cited by
- 164
- References
- 1
- FWCI
- 30.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia. https://app.cochat.ai/papers/10.1159/000017242
- The paper
- Le Bars, P. L., Kieser, M., & Itil, K. Z. (2000). A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000017242
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.